Disclosed is an anticancer prodrug that disturbs energy metabolism in cancer cells to overcome drug resistance. The anticancer prodrug has a structure including a pyruvate dehydrogenase kinase (PDK) inhibitor moiety, a mitochondrial targeting group, and an anthracycline moiety reversibly connected to the PDK inhibitor moiety and the targeting group.
揭示了一种抗癌前药物,它扰乱癌细胞的能量代谢以克服药物抗性。这种抗癌前药物的结构包括一个
丙酮酸脱氢酶激酶(PDK)
抑制剂基团,一个线粒体靶向基团,以及与PDK
抑制剂基团和靶向基团可逆连接的
蒽环类基团。